Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBShield: AC-203 for Generalized Epidermolysis Bullosa Simplex
NCT06073132Phase 3Active, not recruiting
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of AC-203 in epidermolysis bullosa simplex (EBS) (3 arms), sponsored by TWi Biotechnology, Inc. Primary endpoint: Investigator's Global Assessment Treatment Success at 8 weeks. Started Apr 2024; status: active, not recruiting.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT06073132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06073132.